I heard the call a few things from memory: - Gives them cash through end of 2018 - Don't look for another deal (at least in DMD) - May be an opportunity for drug in Becker's MD - Monotherapy is the current focus - Said had others interested but by comments seemed only SRPT made an offer. Said something to the effect of interest before but once got approval more interested. - Said have had partnership discussions on antibiotic
OK you were right but the upfront still puts it in the size that I wouldn't consider it a significant deal
Perhaps not so significant for SRPT but VERY significant for SMMT being they were close to bankruptcy. I'm happy to see the nice up-front and fact they also get low to high-teen royalties in Europe, on top of keeping full rights in the U.S. where it was noted in the CC that there may be 17K DMD patients here. All told, I don't think I've ever been involved with a stock where there has been this obvious of a telegraphed event to come. Harder part for me now is deciding what to do as I still think the stock is really cheap if they demonstrate PoC in clinic but, obviously, there is still plenty of risk that the lead drug could fail in clinic too.
News 
Market Data 
Discover 
